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Abstract Chemokines are involved in the control of
dendritic cell (DC) trafficking, which is critical for the
immune response, namely in allergic contact dermatitis
(ACD). In this work, we investigated by flow cytometry
the effect of the contact sensitizers 2,4-dinitrofluoro-
benzene (DNFB), 1,4-phenylenediamine (PPD) and
nickel sulfate (NiSO4), on the surface expression of the
chemokine receptors CCR6 and CXCR4 in DC. As an
experimental model of a DC we used a fetal skin-derived
dendritic cell line (FSDC), which has morphological,
phenotypical and functional characteristics of skin DC.
Our results show that all the skin sensitizers studied
decreased the membrane expression of the chemokine
receptors CCR6 and CXCR4. In contrast, 2,4-dichlo-
ronitrobenzene (DCNB), the inactive analogue of
DNFB without contact sensitizing properties, was
without effect on the surface expression of these recep-
tors. Lipopolysaccharide (LPS), which induces the
maturation of DC, also reduced surface CCR6 and
CXCR4 expression.
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Introduction
Epidermal skin dendritic cells (DC), namely Langerhans
cells, play an important role in allergic contact derma-
titis (ACD) and other cell-mediated immune reactions.
They constantly monitor the epidermal microenviron-
ment by taking up and processing antigens that can be
recognized, after migration to the lymph nodes, by T
cells [1]. The migration of DC, both to sites of inflam-
mation and to the draining lymph nodes, is dependent
on a switch in the expression of chemokine receptors and
in the production of chemokines [2]. Chemokines con-
stitute a family of structurally related small (67–127
amino acids, 8–14 kDa) chemotactic cytokines that
regulate the migration of leucocytes throughout the
body, both under physiological and inflammatory con-
ditions. They are the only cytokines that act on the
superfamily of G-protein-coupled serpentine receptors
[3], namely class A, which are characterized by high
homology with rhodopsin, the prototypical family
member [4].
In the skin, the migration and epidermal retention of
Langerhans cells is dependent on its expression of
CCR6, which is downregulated as DC mature and mi-
grate to the lymph nodes. CXCR4, the membrane
chemokine receptor for CXCL12, has been related with
the constitutive basal trafficking of leucocytes, namely
DC [2]. Scarce information is available concerning direct
effects of contact sensitizers on chemokine receptor
expression in skin DC. Therefore, the aim of this study
was to investigate whether different contact sensitizers,
namely 2,4-dinitrofluorobenzene (DNFB), 1,4-pheny-
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lenediamine (PPD) and nickel sulfate (NiSO4), modulate
the surface expression of the chemokine receptors CCR6
and CXCR4 in DC. As an experimental model of a DC
we used a fetal skin-derived dendritic cell line (FSDC),
which has morphological, phenotypical and functional
characteristics of a skin DC, the Langerhans cells [5]. As
a positive control we used lipopolysaccharide (LPS),
which was previously shown to induce FSDC activation
[6, 7] and DC maturation [8]. As a negative control we
used 2,4-dichloronitrobenzene (DCNB), the inactive
analogue of DNFB which does not induce ACD.
Materials and methods
Materials
The PE-conjugated monoclonal antibodies against
CCR6 and CXCR4 were purchased from R&D Systems
(Lille, France). DNFB and DCNB were from Sigma-
Aldrich Quı´mica (Madrid, Spain) and PPD was from
Aldrich Chemical Co. (Milwaukee, WI). LPS from
Escherichia coli (serotype 026:B6) was obtained
from Sigma Chemical Co. (St. Louis, MO, USA). Fetal
calf serum was from Biochrom KG (Berlin, Germany)
and trypsin from Invitrogen (Paisley, UK). All other
reagents were from Sigma Chemical Co. (St. Louis, MO,
USA).
Cell culture and chemicals
A fetal mouse skin dendritic cell line (FSDC), kindly
supplied by Dr. G. Girolomoni, was used in the exper-
iments. This cell line has a surface phenotype consistent
with that of Langerhans cell progenitor (H-2d.b+,
I-Ad.b+, CD54+, MHCII+, MHCI+, CD11c+,
CD11b+, B7.2+, CD44+ B220, CD3). After treat-
ment with cytokines, FSDC stimulate allogeneic or
syngeneic T cells in the primary mixed-leukocyte reac-
tion and present haptens to primed T cells in vitro.
Moreover, FSDC derivatized with haptens and injected
either intravenously or subcutaneously efficiently induce
contact sensitivity responses in naı¨ve syngeneic mice [5].
Cells were cultured in endotoxin-free Iscove’s medium
supplemented with 10% (v/v) fetal calf serum, 1% (w/v)
glutamine, 3.02 g/l sodium bicarbonate, 100 lg/ml
streptomycin and 100 U/ml penicillin. For flow cytom-
etry analysis and MTT assay, FSDC were plated at
2·106 cells/well, in 6-well culture plates, or at
0.2·106 cells/well, in 48-well culture plates, respectively,
and then stimulated, for 18 h, with culture medium
alone, or with LPS (2 lg/ml), or with the following
contact sensitizers: PPD (10, 50 lg/ml) and NiSO4
(50 lg/ml), dissolved in saline, DNFB (1, 2.5 lg/ml) and
DCNB (2.5 lg/ml) pre-solubilized in dimethyl sulphox-
ide (DMSO) and diluted in saline. DMSO concentration
never exceeded 0.025% in the culture medium.
MTT assay
Assessment of MTT reduction by metabolically active
cells was made by a colorimetric assay, using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) as previously reported [6]. In four independent
experiments, the average cell viability for FSDC treated,
for 18 hours, with the refereed concentrations of nickel
and PPD was above 90%, and for DNFB it was
respectively 76% and 64%, for 1 lg/ml and 2.5 lg/ml
(data not shown). DCNB and the vehicle DMSO had no
effect on cell viability evaluated by the MTT assay (data
not shown).
Flow cytometric analysis
Briefly, FSDC cells treated with culture medium alone
(control), or with the above refereed chemicals (con-
centrations indicated in the Figs. 1 and 2) were washed
with phosphate buffered saline, and cell pellets were
incubated with PE-conjugated monoclonal antibodies
against CCR6 or CXCR4, for 10 min at room temper-
ature. After washing again with saline, flow cytometry
analysis was performed with FACScalibur flow cytom-
eter and CellQuest software (Becton Dickinson).
Appropriate isotype controls used at the same concen-
tration as the test antibody showed a mean fluorescence
Fig. 1 Effect of contact sensitizers and LPS on CCR6 expression in
FSDC cells. FSDC cells (2·106 cells) were incubated in culture
medium alone (control), or with LPS, or in the presence of different
contact sensitizers, at the indicated concentrations, for 18 h.
Surface expression of CCR6 was analyzed by flow cytometry as
described in material and methods and data are expressed as
percentage of non-treated control cells (100% corresponds to a
mean fluorescence intensity of 29.6±3.5). Each value represents the
mean±SEM from the indicated number of experiments (*P<0.05;
**P<0.01)
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intensity (MFI) similar to the negative (baseline) con-
trol.
Results are presented, in percentage, as the ratio of
MFI of the treated and nontreated cells in each lot of
experiments, according to the formula: CXCR4 or
CCR6 expression (Percentage of control) = (Mean flu-
orescence intensity of chemical-treated cells/mean fluo-
rescence intensity of nontreated cells)x100. MFI of
nontreated control cells (100%) corresponds to
52.7±5.3 and 29.6±3.5, for CXCR4 and CCR6,
respectively. FSDC cells cultured in the same conditions
and subjected to the same experimental protocol for flow
cytometry, but without labeling with monoclonal anti-
bodies (negative baseline control), were always evalu-
ated in parallel experiments (MFI of 3.8±0.6). Cellular
debris was eliminated from the analysis using a gate on
forward and side scatter.
Data analysis
Results are presented as mean ± SEM of the indicated
number of experiments (3–6). Mean values were com-
pared using one-way ANOVA followed by the Dunnett
comparison test. The significance level was 0.05.
Results and discussion
Langerhans cells (LC), the principal DC residing in the
epidermis, typify the sentinel role of immature DC. LC
are known to play a key role in the development of
allergic contact dermatitis (ACD). Following an
encounter with a chemical allergen, LC become acti-
vated and subsequently migrate from the skin to the
draining lymph nodes, undergoing a maturation process
during this journey [1]. After hapten exposure, LC have
been shown to suffer diverse changes, namely internali-
zation of surface MHC class II molecules via endocy-
tosis, induction of tyrosine phosphorylation and
modulation of cell surface markers and cytokine
expression [9–12]. However, the effect of contact aller-
gens on chemokine receptor expression in LC was sel-
dom addressed before.
The chemokine receptors CCR6 and CXCR4 regu-
late the recruitment of antigen-presenting and immu-
nocompetent cells during inflammatory and
immunological responses, namely ACD. In this work we
studied, for the first time, the effect of different skin
sensitizers on CCR6 and CXCR4 surface expression. We
used an organic contact sensitizer, DNFB and its inac-
tive analogue, DCNB, and two other common allergens,
namely nickel sulfate and the arylamine 1,4-phenylen-
ediamine (PPD). FSDC, an immature LC precursor
used in these studies [5], constitutively expresses CXCR4
and CCR6 on its surface, with a mean fluorescence
intensity of 52.7±5.3 and 29.6±3.5, respectively. All the
skin sensitizers decreased membrane expression of the
chemokine receptor CCR6 (Fig. 1), with the strongest
effect observed for the more potent skin sensitizer used,
DNFB. The highest DNFB concentration used (2.5 lg/
ml) decreased CCR6 surface expression, to 51.9±9.5%
of the control. This contrasts with its inactive analogue,
DCNB, which had no effect on CCR6. Accordingly, we
have previously shown in the FSDC cell line that, in
contrast with DNFB, DCNB had no effect on the
expression of other cell activation markers (CD40 and
IL-12 receptor) [13].These results suggest that skin sen-
sitizers decrease surface CCR6 expression, and therefore
may enhance DC migration out of the skin to the lymph
nodes where they can present antigens to T cells. In
agreement with our findings, CCR6 is known to be
constitutively expressed in immature DC, but it is
downregulated as DC mature [3, 14]. LPS, previously
shown to induce maturation of dendritic cells [8, 15, 16],
also reduced membrane expression of CCR6 in FSDC
(Fig. 1), to 69.7±7.8% of the control, although the ef-
fect of LPS was not as significant as that of DNFB and
PPD. This probably occurs because of their strong skin
sensitizing potential, which promote DC activation and
maturation, as observed in other DC [11, 17–23].
Moreover, LPS and these contact sensitizers may induce
different aspects of DC maturation, since the signaling
pathways are also different; LPS acts through TLR4
[15], which is not described as being used by skin sen-
sitizers.
The role of CCR6 in ACD is under current
investigation. In DNFB-induced contact hypersensi-
tivity studies, CCR6-deficient mice developed more
severe and more persistent inflammation than
Fig. 2 Effect of contact sensitizers and LPS on CXCR4 expression
in FSDC cells. FSDC cells (2·106 cells) were incubated in culture
medium alone (control), or with LPS, or in the presence of different
contact sensitizers, at the indicated concentrations, for 18 h.
Surface expression of CXCR4 was analyzed by flow cytometry as
described in Materials and Methods and data are expressed as
percentage of non-treated control cells (100% corresponds to a
mean fluorescence intensity of 52.7±5.3). Each value represents the
mean±SEM from the indicated number of experiments (*P<0.05;
**P<0.01)
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wild-type animals [24]. However, in vivo, both CCR6
and its ligand, CCL20, were markedly upregulated in
chronic inflammatory skin disorders like contact
dermatitis, psoriasis, and atopic dermatitis [25, 26],
where there is an accumulation of DC in the epidermis
[27].
CXCR4, the membrane chemokine receptor for
CXCL12, has been related with the constitutive basal
trafficking of leucocytes [2], and was also investigated
in this work. Our results show that, as observed with
CCR6, all the skin sensitizers tested reduced the
amount of plasma membrane-associated CXCR4 in
FSDC (Fig. 2). DNFB (2.5 lg/ml) reduced CXCR4
expression to 46.7±7.5% of the control (Fig. 2), being
the most potent sensitizer in decreasing CXCR4 sur-
face expression, as observed for the other surface
marker. DCNB was without effect on the surface
expression of this receptor. LPS also decreased
CXCR4 surface expression, to 80.2±5.6%, although
this effect was not statistically significant. In contrast
to our results, a previous in vitro study, using
peripheral blood monocytes-derived DC and methac-
rylates as skin contact sensitizers, showed an increase
in CXCR4 expression [28].
The results obtained in this work demonstrate that,
in vitro, skin sensitizers decrease the surface CCR6
and CXCR4 expression on FSDC, which, in vivo,
might be related with the enhancement of DC
migration out of the skin to the lymph nodes for
antigen presentation to T cells. In this work, we did
not study other markers of FSDC maturation induced
by contact sensitizers and LPS. However, in our pre-
vious work we observed that DNFB and NiSO4 in-
creased FSDC expression of the membrane-associated
proteins CD40 and interleucin (IL) 12 receptor [13],
and that they activated the transcription factor NF-kB
[7, 29, 30], which could be regarded as a cellular
maturation pathway. Moreover, studies performed in
other DC types clearly demonstrate that contact sen-
sitizers induce DC maturation [11, 17–23].
There are two major mechanisms of regulation of
the abundance of chemokine receptors on the cell
surface: altered gene expression and desensitisation
[31]. The skin sensitizers-induced signaling pathway(s)
responsible for the decrease of CCR6 and CXCR4
surface expression in dendritic cells have not yet been
identified. Our preliminary results suggest that CXCR4
and CCR6 receptors undergo desensitisation, since the
decrease in surface expression of the receptors was
already observed 2.5 h after incubation with contact
sensitizers (data not shown). The understanding of
these mechanisms could have profound biological
consequences in ACD by allowing to act upstream of
the current target of anti-inflammatory agents,
through the modulation of surface expression of
chemokine receptors. Therefore, targeting chemokines
and chemokine receptors may offer new opportunities
for therapeutic interventions in ACD and other
chronic inflammatory skin diseases.
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